Department of OBGYN

Santiago Panesso, MD

  • Postdoctoral Associate, Department of Obstetrics, Gynecology & Reproductive Sciences

Santiago Panesso is an international graduate from Colombia. He graduated as a medical doctor, with a distinction in academic research, with experience in a variety of healthcare settings in North and South America. He has experience working in multiple fields through clinical and research experience such as Pediatric Infectious Diseases, Parasitology and now on Ovarian Cancer treatment strategies at MWRI. He has won various scientific awards, including Paul M. Rike Fellowship Award and MWRIF foundation Fellowship Grant.

Education & Training

  • MD, Universidad De Los Andes - Bogota, Colombia

Representative Publications

  • Panesso-Gómez S, IE Rodríguez-Mantilla, Lasso P, Pavia P, Orozco A, Cuellar A, Puerta CJ, Mendoza de Molan, González JM: Trypanosoma cruzi detection in Colombian patients with a diagnosis of esophageal achalasia. AJTMH Mar 2018, 98 (3): 717 - 723 
     
  • Panesso-Gómez S, Conces M, Shimamura S, Talavera MM, Moallem M, Sanchez PJ, Malleske DT: Detection of Cytomegalovirus in Intestinal Tissue of Infants with Necrotizing Enterocolitis and Spontaneous Intestinal Perforation. Journal of Pediatrics, Sep 2019, 214: 34 - 40. 
     
  • Cole AJ, Iyengar M, Panesso-Gómez S, O'Hayer P, Chan D, Delgoffe GM, Aird KM, Yoon E, Bai S, Buckanovich RJ: NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer. JCI insight Mar 2020, 5(7): e131486.
     
  • Cole AJ, Panesso-Gómez S, Shah JS, Ebai TB, Jiang Q, Gumusoglu-Acar E, Bello MG, Vlad A, Modugno F, Edwards RP, Buckanovich RJ . Quiescent ovarian cancer cells, in response to chemotherapy, secrete follistatin to induce chemotherapy resistance in surrounding cells. Clinical Cancer Research (January 2023). Submitted (Accepted)

Clinical Interests/Research Interests

Dr. Panesso is passionate about improving the women’s’ health of patients through research and development of safe innovative therapies. Also be able to push the boundaries of our understanding of the origins of cancer and innovate new pathways of therapeutics through advanced clinical and research training.